Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

240 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
A Phase I and pharmacokinetic study of VNP40101M, a novel sulfonylhydrazine alkylating agent, in patients with refractory leukemia.
Giles F, Thomas D, Garcia-Manero G, Faderl S, Cortes J, Verstovsek S, Ferrajoli A, Jeha S, Beran M, Koller C, Andreeff M, Cahill A, Clairmont C, Sznol M, Kantarjian H. Giles F, et al. Among authors: sznol m. Clin Cancer Res. 2004 May 1;10(9):2908-17. doi: 10.1158/1078-0432.ccr-03-0738. Clin Cancer Res. 2004. PMID: 15131024 Clinical Trial.
Phase I study of cloretazine (VNP40101M), a novel sulfonylhydrazine alkylating agent, combined with cytarabine in patients with refractory leukemia.
Giles F, Verstovsek S, Thomas D, Gerson S, Cortes J, Faderl S, Ferrajoli A, Ravandi F, Kornblau S, Garcia-Manero G, Jabbour E, O'Brien S, Karsten V, Cahill A, Yee K, Albitar M, Sznol M, Kantarjian H. Giles F, et al. Among authors: sznol m. Clin Cancer Res. 2005 Nov 1;11(21):7817-24. doi: 10.1158/1078-0432.CCR-05-1070. Clin Cancer Res. 2005. PMID: 16278404 Clinical Trial.
White paper on adoptive cell therapy for cancer with tumor-infiltrating lymphocytes: a report of the CTEP subcommittee on adoptive cell therapy.
Weber J, Atkins M, Hwu P, Radvanyi L, Sznol M, Yee C; Immunotherapy Task Force of the NCI Investigational Drug Steering Committee. Weber J, et al. Among authors: sznol m. Clin Cancer Res. 2011 Apr 1;17(7):1664-73. doi: 10.1158/1078-0432.CCR-10-2272. Epub 2011 Feb 15. Clin Cancer Res. 2011. PMID: 21325070 Review.
Plasma markers for identifying patients with metastatic melanoma.
Kluger HM, Hoyt K, Bacchiocchi A, Mayer T, Kirsch J, Kluger Y, Sznol M, Ariyan S, Molinaro A, Halaban R. Kluger HM, et al. Among authors: sznol m. Clin Cancer Res. 2011 Apr 15;17(8):2417-25. doi: 10.1158/1078-0432.CCR-10-2402. Epub 2011 Apr 12. Clin Cancer Res. 2011. PMID: 21487066 Free PMC article.
A phase 2 trial of dasatinib in advanced melanoma.
Kluger HM, Dudek AZ, McCann C, Ritacco J, Southard N, Jilaveanu LB, Molinaro A, Sznol M. Kluger HM, et al. Among authors: sznol m. Cancer. 2011 May 15;117(10):2202-8. doi: 10.1002/cncr.25766. Epub 2010 Nov 29. Cancer. 2011. PMID: 21523734 Free PMC article. Clinical Trial.
240 results